The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-G7 vaccine pledge is just a drop in the ocean, campaigners say

Fri, 11th Jun 2021 07:37

* G7 to pledge 1 billion vaccine doses

* Campaigners: G7 too slow, lacks ambition

* Britain to give 100 million doses

* UK says some countries using vaccines to hold sway
(Adds details, reaction)

By Kate Holton and Alistair Smout

CARBIS BAY, England, June 11 (Reuters) - A Group of Seven
plan to donate 1 billion COVID-19 vaccine doses to poorer
countries lacks ambition, is far too slow and shows Western
leaders are not yet up to the job of tackling the worst public
health crisis in a century, campaigners said on Friday.

British Prime Minister Boris Johnson said he expected G7
leaders to agree the donations as part of a plan to inoculate
the world's nearly 8 billion people against the coronavirus by
the end of next year.

After U.S. President Joe Biden vowed to supercharge the
battle against the virus with a donation of 500 million Pfizer
shots, Johnson said Britain would give at least 100
million vaccines within the next year. Other pledges may follow.

But health and anti-poverty campaigners said that while the
donations were a step in the right direction, Western leaders
had shown a lack of ambition and a failure to grasp the
exceptional efforts needed to beat the virus.

"The new U.S. and UK commitments are a step in the right
direction, but they don't go far enough, fast enough," said Alex
Harris, director of government relations at Wellcome, a
London-based science and health charitable foundation.

"What the world needs is vaccines now, not later this year.
At this historic moment, the G7 must show the political
leadership our crisis demands," said Harris. "We urge G7 leaders
to raise their ambition."

The race to bring an end to a pandemic that has killed
around 3.9 million people globally and sown social and economic
destruction will feature prominently at the three-day summit
which begins on Friday in the English seaside resort of Carbis
Bay.

British foreign minister Dominic Raab warned that other
countries were using vaccines as diplomatic tools to secure
influence. Britain and the United States said their
donations would come with no strings attached.

COVID-19 has ripped through the global economy, with
infections reported in more than 210 countries and territories
since the first cases were identified in China in December 2019.

'FAILURE'

As most people need two vaccine doses, and possibly booster
shots to tackle emerging variants, campaigners said the G7
commitments marked a start but that world leaders needed to go
much further, and much faster.

"If the best G7 leaders can manage is to donate 1 billion
vaccine doses then this summit will have been a failure,"
Oxfam's health policy manager Anna Marriott said, adding that
the world would need 11 billion doses to end the pandemic.

Vaccination efforts so far are heavily correlated with
wealth: the United States, Europe, Israel and Bahrain are far
ahead of other countries. A total of 2.2 billion people have
been vaccinated according to Johns Hopkins University data.

Oxfam also called on G7 leaders to support a waiver on the
intellectual property behind the vaccines.

French President Emmanuel Macron has said intellectual
property rights should not hinder access to vaccines during a
pandemic, and that Paris would join South Africa in proposing
that nations work on a limited easing of rules.

Biden has already backed a proposed patent waiver for
vaccines targeting the novel coronavirus that advocates say
could help boost availability.

VACCINE OWNERSHIP?

The pharmaceutical industry has opposed it, saying it would
stifle innovation and do little to effectively increase vaccine
supplies. Britain, which backed Oxford-AstraZeneca's
not-for-profit shot, has said a patent waiver is not necessary.

Of the 100 million British shots, 80 million will go to the
COVAX programme led by the World Health Organization (WHO) and
the rest will be shared bilaterally with countries in need.

Johnson echoed Biden in calling on his fellow leaders to
make similar pledges and for pharmaceutical companies to adopt
the not-for-profit model during the pandemic. The U.S. Pfizer
donations will be supplied at cost.

Leaving poorer countries to deal with the pandemic alone
risks allowing the virus to further mutate and evade vaccines,
scientists have warned. Charities have also said that logistical
support will be needed to help administer large numbers of
vaccines in poorer countries.

The British doses will be drawn from the stock it has
already procured for its domestic programme, and will come from
suppliers Oxford-AstraZeneca, Pfizer-BioNTech, Janssen, Moderna
and others.

(Reporting by Kate Holton and Alistair Smout; Editing by Guy
Faulconbridge, Alex Richardson and Emelia Sithole-Matarise)

More News
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.